Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The molybdenum cofactor biosynthetic pathway comprises a sequence of conserved enzymatic steps that produce the molybdenum cofactor (Moco), a pterin-based ligand essential for the function of almost all molybdoenzymes. These enzymes catalyze key redox reactions in carbon, nitrogen, and sulfur metabolism in diverse organisms, including bacteria, plants, and animals[1][2][3][4][5][6]. Genes and enzymes involved in this pathway include those that synthesize cyclic pyranopterin monophosphate (cPMP), convert cPMP to molybdopterin (MPT), insert molybdate to form Moco, and potentially modify Moco by nucleotide addition[1][2][3]. Defects in this pathway result in the loss of the function of all molybdoenzymes, causing severe metabolic disorders, but the pathway itself is not a traditional drug or therapeutic target as defined for individual receptors or enzymes[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Molybdenum cofactor biosynthetic pathway.